Introduction
Serum response factor (SRF) is a transcription factor that plays a critical role in embryonic development as well as the growth and maintenance of all differentiated muscle types. [1] [2] [3] SRF belongs to the MADS (MCM1, Agamous, Deficiens, and SRF) superfamily of transcription factors, which recognize 10-nucleotide (CC [A/T] 6 GG) sequences called CArG boxes through a DNA binding domain. 4 In smooth muscle cells (SMCs), SRF drives expression of contractile and cytoskeletal proteins through recognition and binding of these CArG boxes, which are primarily located in the promoter and intronic regions of most SMC-specific genes. 5, 6 The role of SRF as a "master switch" for contractility is further demonstrated by the loss of contractile phenotype with loss of SRF expression in muscle cells and the differentiation of fibroblasts to myofibroblasts with SRF overexpression in cell culture. 7 The importance of SRF in embryonic development has been previously demonstrated in a SM22-Cre knockout (KO) system in mice that resulted in Srf deletion in the majority of cardiomyocytes and vascular smooth muscle cells. 8 Interestingly, the SM22-Cre Srf KO mice died at embryonic day (E) 11.5 and had severe structural defects in cardiomyocytes and SMCs. In a similar transgenic mouse model that restricts deletion of Srf to primarily SMCs through the expression cassette Myh11-Cre-EGFP, we confirm the prenatal lethality of congenital Srf deletion in GI and cardiac muscle cells. We also provide new evidence that expression of SRF in SMCs is lost in a surgically induced hypertrophy model, in human rectal prolapse tissue, and in cell culture. Importantly, we present a new finding that the loss of SRF protein expression during dedifferentiation of SMCs may be accompanied by a gain of platelet-derived growth factor receptor alpha (PDGFR) expression during proliferative expansion. Collectively, our data further supports the critical role of SRF in contractile tissues and its loss in pathologic states.
M aterials and M ethods

Generation of Congenital Srf Knockout Mice
The SMC-specific congenital Srf KO mouse line,
Tg(Myh11-Cre-EGFP);Srf lox/lox
, was generated by cross-breeding a Srf lox/lox female homozygote mouse (The Jackson Laboratory, Bar Harbor, ME, USA) with a Tg(Myh11-Cre-EGFP) male mouse 9 according to procedures approved by the Institutional Animal Care and Use Committee at the University of Nevada, Reno.
Ultrasound Biomicroscopy
Pregnant dams were sedated with isoflurane and scanned with a high frequency ultrasound system containing a 32-MHz linear array transducer (VisualSonics Vevo 2100, Toronto, ON, Canada) for diagnosis of congenital heart defects. Ultrasound scanning was performed according to the manufacturer's instructions and recorded in real-time.
Partial Obstruction Surgery
One month old transgenic mice with the genotypes Tg(Myh11-Cre-EGFP), Tg(Pdgfra-EGFP), or Tg(Myh11-Cre-EGFP); Tg(Pdgfra-EGFP) were used for intestinal partial obstruction surgeries as previously described. 10 Briefly, a silicon ring was surgically placed on the distal ileum just oral to the cecum. As a modification to the previously described protocol, a 5-0 polyglycolic acid suture was placed through the ends of the silicon ring opening to secure its closing. After ∼2 weeks, the obstructed mice were sacrificed along with the sham operated control mice for histological and molecular analyses. Of note, the 
Histological Analysis
Srf KO and WT fetuses from gestational days 18 to 19 were fixed in Bouin's fixative for at least 24 hours followed by washing in 70% ethanol for several days for picric acid removal. Fixed embryos were dehydrated through an alcohol gradient, embedded in paraffin, sectioned, and stained with hematoxylin and eosin (H&E). Three sections from at least 2 different embryos were analyzed. Small intestine tissues from partially obstructed and sham control animals were fixed in 4% paraformaldehyde/phosphate-buffered saline (PBS) for 1 hour 20 minutes at 4 o C prior to dehydration through an alcohol gradient and H&E staining. Paraffin embedded sections of human rectal prolapse and control colon tissues were obtained from Stanford University Medical Center, Palo Alto, California, USA, where Institutional Review Board approval was obtained. Sections were examined using the iScan Coreo scanner (Ventana Medical Systems, Tucson, AZ, USA).
Immunohistochemical Analysis
Immunofluorescence microscopy of the jejunum was performed as previously described with minor modifications. 11 
Cell Culture
The jejunum was dissected from 3-week-old transgenic Myh11-Cre-EGFP mice, which expressed EGFP in SMCs, and the muscularis (n = 3) was gently peeled off from the mucosa and incubated for 30 minutes at 37 o C in a collagenase-based dissociation solution containing 1.3 mg/mL collagenase (type II; Worthington Biochemical, Freehold, NJ, USA), 2 mg/mL bovine serum albumin (BSA; Sigma, St. Louis, MO, USA), 2 mg/mL trypsin inhibitor (Sigma), and 0.27 mg/mL ATP (Sigma), 10 mL of calcium-free Hank's balanced salt solution (pH 7.0). The tissue was then bluntly triturated with a glass pipette until all of the tissue was broken down in the media. Single cells were obtained by using a 30 m Pre-Separation Filter (Miltenyi Biotec, Bergisch Gladbach, Germany) and seeded in a 4-well glass slide Lab-Tek II CC2 glass chamber slide (Thermo 
Quantitative Polymerase Chain Reaction
Total RNAs were extracted from the cultured cells, cDNAs were reverse transcribed from the total RNAs, and QPCR was performed on the cDNAs as previously described. 12 All primers used for RT-PCR are shown in Table. Statistical Methods
Western blot and QPCR data were analyzed for statistical significance by using Student's test. Measured variables were expressed as mean ± SEM. The differences in mean values between 2 animal groups (sham and hypertrophy) were evaluated and considered significantly different when P < 0.05 or P < 0.01.
Results
Serum Response Factor Is Required for Prenatal Gastrointestinal Tract and Cardiac Development
All congenital homozygous Srf KO (KO hereafter) mice died before birth while heterozygous Srf KO and wild type mice were viable. Multiple breeding combinations consisting of homozygous floxed (Srf lox/lox ) or heterozygous floxed (Srf lox/+ ) mice with Cre males and females resulted in birth of ~100 pups that were either wild type or Srf KO heterozygotes. We, therefore, examined the embryos of pregnant females. Figure 1A shows a representative mother that had 7 embryos at E15. Genotyping of the embryos identified 4 heterozygous KO (Srf ) in agreement with Mendelian genetics. Grossly, there was no significant difference in size between homozygous KO, heterozygous KO, and WT embryos (Fig. 1B) . However, sagittal cross sections of whole fetuses at E18 showed that internally, the KO fetus was grossly underdeveloped compared to the WT fetus, and the severe underdevelopment of the GI tract in the KO fetus was particularly striking (Fig. 1C) .
Interestingly, real-time doppler ultrasonography of the fetal heart (echocardiogram) also revealed that cardiac contractility, ejection fraction, and blood flow were significantly weaker in the KO fetus than WT fetus at E18 ( Fig. 1D and Supplementary Video). The fetal defects of the congenital Srf KO mouse suggested that SRF is essential for development of the GI tract and heart as well as overall survival of the fetus in utero. In a parallel set of experiments, we also generated an inducible SMC-specific Srf KO mouse system, which showed that SRF is required for maintenance of a differentiated phenotype and prevention of degeneration and apoptosis in adult GI SMCs (unpublished data). Collectively, these animal studies also indicated that SRF is essential for development and maintenance of mature GI SMCs within the GI tract.
Serum Response Factor and PDGFR Are Linked to Smooth Muscle Cell Hypertrophy
Since SMCs dedifferentiate into a proliferating phenotype and hypertrophy under pathological obstruction, 13 we hypothesized that SRF expression in GI SMCs decreases during the re- sulting compensatory process. To test our hypothesis, we looked for changes in SRF expression in hypertrophic GI tissue using a surgically induced partial obstruction mouse model. 10 Two weeks after placement of a small silicon ring on the distal ileum, the jejunum and ileum were severely distended compared to the large ring sham control ( Fig. 2A) . H&E staining confirmed the presence of significant hypertrophy in the longitudinal and circular muscle layers of partially obstructed jejunum (Fig. 2B) , and western blot analysis showed that expression levels of SRF protein in the jejunum smooth muscle increased with partial obstruction, whereas expression levels of MYH11 and SM22 did not change ( Fig. 2C and 2D ). To examine the localization of SRF in the GI tract, we generated Myh11 cytoplasmic EGFP ; Pdgfra nuclear EGFP mice and looked at SRF expression in the smooth muscle via immunofluorescence labeling. We discovered that there were at least 2 distinct populations of cells expressing SRF in the muscularis (Fig. 3A and 3B) In both surgically obstructed and sham control mice, there was little proliferative activity, as detected by anti-Ki67 staining, in differentiated SMCs expressing cEGFP (Fig. 4) . However, cells expressing low levels of nEGFP (PDGFR) in hypertrophied jejunum, which were located just outside of the longitudinal muscle layer (subserosal area), displayed higher levels of cell cycling although the Ki67 signal was relatively weaker in this population of cells (Fig. 4, bottom panels) . Other areas of the cross section that showed high levels of Ki67 staining included the mucosal epithelia and submucosa in both obstructed and sham control jejunum (Fig. 4) .
To recapture the possible phenotypic switch from SMCs to PDGFR + cells in vitro, we cultured primary jejunal SMCs from Myh11-Cre-EGFP or Pdgfra-EGFP mice for up to 8 days (Fig. 5) . cEGFP expression in differentiated SMCs from Myh11-Cre-EGFP mice was detectable by epifluorescence microscopy at day 0 and day 1 of cell culture but was abruptly lost by day 2 (Fig. 5A ). In contrast, dispersed SMCs from Pdgfra-EGFP mice began to express nEGFP at day 2 indicating a phenotypic transition to PDGFR + cells (Fig. 5B) . QPCR analysis of the dispersed cells in culture at differing time points revealed that transcription of Srf and its target gene Myh11 essentially shut down within 24 hours of incubation (Fig. 5C ). Srf expression began to resume at low levels on day 8, whereas Myh11 expression remained silent. The data indicated that both Srf and Myh11 genes turned off quickly in cell culture conditions as SMCs began to proliferate and that the residual Myh11 promoter driven cEGFP remained in SMCs up to 1 day following silencing of the genes. The cell culture and QPCR data also showed that SMCs grown in culture may lose contractile proteins, such as MYH11, with the gain of PDGFR expression as early as day 2 of culture and that the SRF low cells expressing PDGFR seen in the partial obstruction model (Figs. 3 and 4) may represent a population of cells that may have dedifferentiated from SMCs to proliferate as a hypertrophic and hyperplastic response.
The vascular SMC phenotype is regulated by SRF and its cofactors myocardin (MYOCD) and ELK1, an ETS domain-containing protein.
14 Therefore, we also examined the Myocd and Elk1 mRNA transcript levels of cultured SMCs and hypertrophied jejunum smooth muscle. Myocd expression declined gradually during cell culture and was also significantly decreased in hypertrophic tissue (Fig. 5D) 
Loss of Serum Response Factor in Smooth Muscle Cells Is Implicated in the Pathophysiology of Rectal Prolapse in Humans
To assess the relevance of our studies to human GI pathologies, we examined expression of SRF in human colorectal prolapse tissue. The histological morphology of healthy colon was well organized with distinct circular and longitudinal muscle layers present in between the submucosa and subserosa (Fig. 6A) . In contrast, prolapse tissue contained disorganized and dysplastic muscle layers that were in abnormal contact with the mucosa juxtaposed to a highly disorganized and dysplastic serosa layer. Robust levels of SRF expression were detected by immunohistochemistry in the nuclei of SMCs of control colon but barely detectable in rectal prolapse tissue (Fig. 6B) . These findings mirrored those of the mouse partial obstruction model (Fig. 3B) . Taken together, our human rectal prolapse tissue studies support the hypothesis that SRF is required for SMC differentiation and maintenance and that pathological loss of SRF in SMCs may trigger SMC dedifferentiation and growth leading to hypertrophy and hyperplasia in the GI smooth muscle.
Discussion
To our knowledge, this is the first animal study that has demonstrated a developmental defect of the GI smooth muscle caused by a congenital Srf deficiency. SRF is an essential regulator for muscle cell proliferation and differentiation in skeletal, 15 cardiac, 16 and smooth muscle, 5 and a global Srf gene mutagenesis results in a severe gastrulation defect that is embryonic lethal. 1 Cardiacspecific (Myh6 promoter driven) and vascular-specific (SM22 promoter driven) knockouts of Srf are also embryonic lethal due to a severe cardiac defect. 8, 17 The expression of SM22 (Tagln) is relatively restricted to vascular SMCs in adults 18 in addition to cardiac muscle cells in embryos. 19 However, SM22 is also expressed in proliferating and differentiated SMCs 20 as well as PDGFR + cells in GI smooth muscle (transcriptome analysis, unpublished data). To target SMCs specifically, we generated a Myh11 promoter driven Srf KO mouse model. MYH11, which is expressed in SMCs of the GI tract by E13.5, 9 is widely considered the most selective marker for differentiated SMCs. 21 In this KO system, the Srf gene is deleted by Cre under the control of the Myh11 promoter at E13.5. However, SRF protein synthesized prior to E13.5 may continue to reside within cells for several days.
In our congenital studies, the cardiac and GI defects from Myh11 promoter driven Srf KO manifested at E18, which is later than the time of manifestation for Myh6 (E12.5) and SM22 (E11.5) promoter driven KOs. 8, 17 This phenotypic discrepancy may be partially explained by the differential timing of promoter activation in different cell populations during development. Since MYH11 is the most distinctive marker for differentiated SMCs, the prenatal GI and cardiac defects revealed in this study most accurately represent the phenotypes that result from congenital deletion of Srf in SMCs. The manifestation of cardiac dysfunction was not anticipated since MYH11 is not expressed in cardiomyocytes. However, it is conceivable that the Srf KO may have disrupted the normal vascularization of the developing heart in utero since MYH11 is expressed in vascular SMCs. Our congenital Srf KO studies along with the 2 previously described phenotypes emphasize the critical nature of SRF in the development of prenatal GI smooth muscle and cardiac muscle. The phenomena of SMC hypertrophy and hyperplasia, which occurs during partial bowel obstruction, has been previously well described. 13, 22, 23 Inflammation may also cause SMC hypertrophy within the GI tract. 24, 25 However, the molecular mechanism remains less understood. Our in vivo and in vitro data indicated that under the physiologic stress of partial obstruction, intestinal SMCs may lose expression of SRF and characteristic contractile proteins in favor of a dedifferentiated phenotype capable of proliferation. In vascular SMCs, SRF regulates expression of contractile proteins mainly through its cofactors MYOCD (differentiation) and ELK1 (dedifferentiation). 14 In contrast, however, our data in Figures 3 and 5 suggest that the SMC phenotype in intestinal obstruction may be regulated directly by SRF rather than via ELK1. Elk1 expression was minimal at the beginning and did not increase in cell culture and hypertrophied jejunal smooth muscle (Fig. 5 ) although previous studies have reported ELK1 induction in vascular injury. 26 In this vascular injury model, phosphorylated ELK1 repressed the SM22 gene. However, in our partial intestinal obstruction model, SM22 protein levels were not affected by hypertrophy of the jejunal smooth muscle (Fig. 2C ). In addition, our transcriptome data showed that little or no Elk1 was expressed in both jejunal SMCs and colonic SMCs, whereas Srf was abundantly expressed in a SMC-specific manner. 27 These observations support a model for direct SRF regulation of the GI SMC phenotype during intestinal obstruction, which differs from that of vascular SMCs. Whether expression of SRF and contractile proteins (myosin heavy chains) increases or decreases with intestinal smooth muscle hypertrophy has been the subject of controversy. 13, 28 The discrepancy between contradictory findings by different investigators may be explained by the dynamic stages of the hypertrophic response at which the tissues were examined. For instance, Chen et al 13 found that SRF and contractile protein in whole muscle tissue were down-regulated at the beginning of hypertrophy but later restored to the control levels. Our Western blot data indicated that SRF levels increased after 2 weeks of partial obstruction but that MYH11 levels remained unchanged. 31, 37 We found that each subtype was differentially remodeled during partial intestinal obstruction. However, further studies are needed to determine whether any of these subtypes can display plasticity in the remodeling response.
Finally, we have also demonstrated the pathologic loss of SRF expression in human rectal prolapse tissue. The question of whether loss of SRF in human SMCs is associated with a gain of PDGFR expression and proliferative activity as is in mice should be addressed by further studies. In summary, we have shown that SRF is required for the development of prenatal SMCs and the maintenance of its differentiated phenotype in adult SMCs. The loss or down-regulation of SRF is directly linked to the pathological transitions of SMCs, which includes degeneration during myopathy or proliferation of PDGFR low cells during obstruction induced hypertrophy (Fig. 7) . This study offers new insight into the direct role of SRF in the plasticity of pathologic SMCs.
